logo

FDA Calendar

PDUFA dates and FDA Panel Review dates are very important catalysts because they are ‘make or break events’ for biotech stocks.

The goal date set by the FDA for announcing its decision on a company’s New Drug Application/ Biologics License Application/sBLA/sNDA after reviewing the applications is known as the PDUFA date.

Usually, the stocks experience a run-up going into the scheduled FDA Approval decision/FDA Panel review events. So, having prior knowledge of the key dates goes a long way toward maximizing profit or minimizing loss while investing in the volatile biotech stocks.

Listed below are large cap, mid cap and small cap stocks with pending regulatory catalysts.

Get in-depth analysis and insight on investing in the high-stakes Biotech and Pharma sectors. Check out RTT Biotech Investor and our Biotech Home Page.
Company Name
Drug
Event
Outcome
Details
Pfizer Inc.
(PFE)
Comirnaty vaccine (BLA)
Jan 2022
FDA decision on Comirnaty vaccine to prevent COVID-19
FDA approved COMIRNATY to prevent COVID-19 in individuals 16 years of age and older on Aug.23, 2021-
BioNTech
(BNTX)
Comirnaty vaccine (BLA)
Jan 2022
FDA decision on Comirnaty vaccine to prevent COVID-19
FDA approved COMIRNATY to prevent COVID-19 in individuals 16 years of age and older on Aug.23, 2021-
Amgen Inc.
(AMGN)
Tezepelumab (BLA)
Q1 2022
FDA decision on Tezepelumab in the treatment of asthma
FDA approved Tezepelumab, under brand name TEZSPIRE, for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma on Dec.17, 2021-
BioXcel Therapeutics, Inc.
(BTAI)
BXCL501 (NDA)
01/05/2022
FDA decision on BXCL501 For Acute Treatment Of Agitation Associated With Schizophrenia & Bipolar Disorders I and II
On Dec.1, 2021, the FDA notified the company that the decision date has been postponed to APR.5, 2022-
GlaxoSmithKline PLC
(GSK.L, GSK)
Cabotegravir (NDA)
01/24/2022
FDA decision on injectable cabotegravir long-acting for prevention of HIV
FDA approved injectable Cabotegravir long-acting, under brand name Apretude, for prevention of HIV on Dec.20, 2021 -
Pfizer Inc.
(PFE)
Cabotegravir (NDA)
01/24/2022
FDA decision on injectable cabotegravir long-acting for prevention of HIV
FDA approved injectable Cabotegravir long-acting, under brand name Apretude, for prevention of HIV on Dec.20, 2021-
Bristol-Myers Squibb Co.
(BMY)
Mavacamten (NDA)
01/28/2022
FDA decision on Mavacamten to treat symptomatic obstructive hypertrophic cardiomyopathy
On Nov.19, 2021, the FDA extended the decision date on Mavacamten to Apr.28, 2022-
Roche Holding AG
(RHHBY)
Faricimab (BLA)
01/29/2022
FDA decision on Faricimab for the treatment of wet, or neovascular, age-related macular degeneration (AMD) and diabetic macular edema as well as for diabetic retinopathy
-
Eton Pharmaceuticals, Inc
(ETON)
Zonisamide oral suspension (NDA)
01/29/2022
FDA decision on Zonisamide for the treatment of partial seizures in patients with epilepsy
-
Regeneron Pharmaceuticals
(REGN)
Libtayo (sBLA)
01/30/2022
FDA decision on Libtayo for patients with recurrent or metastatic cervical cancer whose disease progressed on or after chemotherapy
-

ALSO READ - COVID-19 Drugs In Development Calendar which lists Companies that are in Race to find a Treatment or Vaccine for the Novel Coronavirus.

Buy this Content


Nevro Corp. (NVRO) announced receipt of FDA approval for expanded labeling for its Senza Spinal Cord Stimulation System for the treatment of Non-Surgical Refractory Back Pain. The approval is specific to Nevro's 10 kHz Therapy. Keith Grossman, Chairman, Chief Executive Officer and President of Nevro,...
AstraZeneca Plc (AZN.L, AZN) announced Wednesday positive results from the TOPAZ-1 Phase III trial with Imfinzi (durvalumab) in patients with 1st-line advanced biliary tract cancer or BTC. Imfinzi in combination with standard-of-care chemotherapy, demonstrated a statistically significant and clinically...
A second Phase 3 trial, PRIME, which evaluated Dupixent (dupilumab) in adults with uncontrolled prurigo nodularis, a chronic type 2 inflammatory skin disease, met its primary and key secondary endpoints. The trial result showed that Dupixent significantly reduced itch and skin lesions compared to placebo...
Read More
In Florida, more and more patients are looking for approval of marijuana cards as part of the state's medical marijuana program and in this context, lawmakers are making the process easier for them. Certain state lawmakers are introducing changes to the medical marijuana program to make easier the access...
A week after setting an all-time world record of 1.48 million new Covid cases in a day in the United States, daily cases again broke the dreaded 1 million mark on Tuesday. With 10,63000 new cases, the total number of people infected with coronavirus in the U.S. has risen to 67,597,794, according to the latest data from Johns Hopkins University. North Carolina reported the most number of cases -
Researchers at the Karolinska Institutet in Sweden, in collaboration with international scientists, have finished an extensive international validation of artificial intelligence or AI for the diagnosis and grading of prostate cancer. The study shows that AI systems can identify and grade prostate cancer...
Read More